Format

Send to

Choose Destination
F1000Prime Rep. 2014 May 6;6:35. doi: 10.12703/P6-35. eCollection 2014.

Advances in understanding and treating dystrophic epidermolysis bullosa.

Author information

1
Stem Cell Institute and Division of Blood and Marrow Transplantation, Department of Pediatrics, University of Minnesota Medical School 420 Delaware Street SE, MMC 366 Minneapolis, MN 55455 USA.

Abstract

Epidermolysis bullosa is a group of inherited disorders that can be both systemic and life-threatening. Standard treatments for the most severe forms of this disorder, typically limited to palliative care, are ineffective in reducing the morbidity and mortality due to complications of the disease. Emerging therapies-such as the use of allogeneic cellular therapy, gene therapy, and protein therapy-have all shown promise, but it is likely that several approaches will need to be combined to realize a cure. For recessive dystrophic epidermolysis bullosa, each particular therapeutic approach has added to our understanding of type VII collagen (C7) function and the basic biology surrounding the disease. The efficacy of these therapies and the mechanisms by which they function also give us insight into developing future strategies for treating this and other extracellular matrix disorders.

Supplemental Content

Full text links

Icon for Faculty of 1000 Icon for PubMed Central
Loading ...
Support Center